TRDA (Entrada Therapeutics) Research & Development : $120.2 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Entrada Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Entrada Therapeutics's Research & Development for the three months ended in Sep. 2024 was $31.3 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $120.2 Mil.

Entrada Therapeutics Research & Development Historical Data

The historical data trend for Entrada Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entrada Therapeutics Research & Development Chart

Entrada Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

8.22

21.10

35.93

66.61

99.88

Entrada Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Research & Development	Get a 7-Day Free Trial														22.19	28.29	28.61	32.04	31.26

Entrada Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $120.2 Mil.

Entrada Therapeutics (NAS:TRDA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Entrada Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Entrada Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Design Center Place, Suite 17-500, Boston, MA, USA, 02210

Website

https://www.entradatx.com

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Executives

Natarajan Sethuraman	officer: Chief Scientific Officer	6 TIDE STREET, BOSTON MA 02210
Kory James Wentworth	officer: Chief Financial Officer	6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210
Nathan J Dowden	officer: Chief Operating Officer	6 TIDE STREET, BOSTON MA 02210
Dipal Doshi	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Peter S Kim	director	ONE MERCK DRIVE, P.O. BOX 100, WHITEHOUSE STATION X1 08889
Nerissa Kreher	officer: Chief Medical Officer	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Gina Chapman	director	C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403
Bernhardt G Zeiher	director	ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210
Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Todd Foley	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Felix Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
John F Crowley	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
5am Ventures V, L.p.	10 percent owner	2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Mpm Bioventures 2018, L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142